Psychosis in Elderly Patients: Classification and Pharmacotherapy

Journal of Geriatric Psychiatry and Neurology

Volumn 16, Issue 4, 2003, Pages 199-206

  Mintzer, Jacobo ^a   Targum, Steven D ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Clinical Studies Ltd   (United States)

Author keywords

Atypical antipsychotics; Elderly; Pharmacotherapy; Psychosis

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SELEGILINE; SEROTONIN AGONIST; ZIPRASIDONE;

ALZHEIMER DISEASE; ANAMNESIS; ANXIETY DISORDER; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DELUSION; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; EPIDEMIOLOGICAL DATA; EXTRAPYRAMIDAL SYMPTOM; GENETIC RISK; GLUCOSE METABOLISM; HALLUCINATION; HUMAN; INCIDENCE; METABOLIC DISORDER; NAUSEA; ONSET AGE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SENESCENCE; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SYMPTOM; TARDIVE DYSKINESIA; TREATMENT INDICATION; TREATMENT PLANNING; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

AGE FACTORS; AGED; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DYSKINESIA, DRUG-INDUCED; HUMANS; PARKINSON DISEASE; POLYPHARMACY; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SEROTONIN;

EID: 0345303864     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/0891988703258658     Document Type: Review

References (91)

1. Gilley DW, Wilson RS, Beckett LA, Evans DA. Psychotic symptoms and physically aggressive behavior in Alzheimer's disease. J Am Geriatr Soc 1997; 45(9):1074-1079.
2. Zarit SH, Todd PA, Zarit JM. Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist 1986; 26(3):260-266.
3. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-clinical global impression of change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S22-S32.
4. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990; 147(8):1049-1051.
5. Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997; 277(10):806-812.
6. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997; 278(16):1363-1371.
7. Magni E, Binetti G, Bianchetti A, Trabucchi M. Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol 1996; 9:123-126.
8. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 1994; 51(7):676-681.
9. Daniel DG. Antipsychotic treatment of psychosis and agitation in the elderly. J Clin Psychiatry 2000; 61(suppl 14):49-52.
10. Kuzuhara S. Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma. J Neurol 2001; 248(suppl 3):III28-III31.
11. Stoppe G, Brandt CA, Staedt JH. Behavioural problems associated with dementia: the role of newer antipsychotics. Drugs Aging 1999; 14(1):41-54.
12. Zayas EM, Grossberg GT. The treatment of psychosis in late life. J Clin Psychiatry 1998; 59(suppl 1):5-12.
13. Sajatovic M. Schizophrenia in the elderly: guidelines for management. Cent Nerv Syst Drugs 2000; 13(2):103-115.
14. Targum S. Treating psychotic symptoms in elderly patients. Primary Care Companion J Clin Psychiatry 2001; 3:156-163.
15. McDowell I. Alzheimer's disease: insights from epidemiology. Aging (Milano) 2001; 13(3):143-162.
16. Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000; 8(1):29-34.
17. Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 2001; 15(4):169-173.
18. Bassiony MM, Steinberg MS, Warren A, et al. Delusions and hallucinations in Alzheimer's disease: prevalence and clinical correlates. Int J Geriatr Psychiatry 2000; 15(2):99-107.
19. Zimmer JG, Watson N, Treat A. Behavioral problems among patients in skilled nursing facilities. Am J Public Health 1984; 74(10):1118-1121.
20. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989; 146(5):577-587.
21. Tariot PN, Podgorski CA, Blazina L, Leibovici A. Mental disorders in the nursing home: another perspective. Am J Psychiatry 1993; 150(7):1063-1069.
22. Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000; 54(10):1965-1971.
23. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Press, 2000.
24. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47(5):1113-1124.
25. St. Clair D. Apolipoprotein E gene in Parkinson's disease, Lewy body dementia and Alzheimer's disease. J Neural Transm Suppl 1997; 51:161-165.
26. Sweet RA, Kamboh MI, Wisniewski SR, et al. Apolipoprotein E and alpha-1-antichymotrypsin genotypes do not predict time to psychosis in Alzheimer's disease. J Geriatr Psychiatry Neurol 2002; 15:24-30.
27. Peyser CE, Naimark D, Zuniga R, Jeste DV. Psychoses in Parkinson's disease. Semin Clin Neuropsychiatry 1998; 3(1):41-50.
28. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol 2000; 20(1):54-60.
29. Wolters EC, Berendse HW. Management of psychosis in Parkinson's disease. Curr Opin Neurol 2001; 14(4):499-504.
30. Wolters EC. Intrinsic and extrinsic psychosis in Parkinson's disease. J Neurol 2001; 248(suppl 3):III22-III27.
31. Cummings JL, Trimble MR, Hales RE. Clinical neuropsychiatry. In: Hales RE, Yudofsky SC, Talbott JA, eds. Textbook of psychiatry. Washington, DC: American Psychiatric Press, 1999:1667-1991.
32. Arnulf I, Bonnet AM, Damier P, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000; 55(2):281-288.
33. Hafner H, an der Heiden W. Epidemiology of schizophrenia. Can J Psychiatry 1997; 42(2):139-151.
34. Loranger AW. Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry 1984; 41(2):157-161.
35. Harris MJ, Jeste DV. Late-onset schizophrenia: an overview. Schizophr Bull 1988; 14(1):39-55.
36. Castle DJ, Murray RM. The epidemiology of late-onset schizophrenia. Schizophr Bull 1993; 19(4):691-700.
37. Hafner H, Hambrecht M, Loffler W, et al. Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life cycle. Psychol Med 1998; 28(2):351-365.
38. Riecher-Rossler A, Loffler W, Munk-Jorgensen P. What do we really know about late-onset schizophrenia? Eur Arch Psychiatry Clin Neurosci 1997; 247(4):195-208.
39. Lindamer LA, Lohr JB, Harris MJ, et al. Gender-related clinical differences in older patients with schizophrenia. J Clin Psychiatry 1999; 60(1):61-69.
40. Brodaty H, Sachdev P, Rose N, et al. Schizophrenia with onset after age 50 years. I: phenomenology and risk factors. Br J Psychiatry 1999; 175:410-415.
41. Rivkin P, Kraut M, Barta P, et al. White matter hyperintensity volume in late-onset and early-onset schizophrenia. Int J Geriatr Psychiatry 2000; 15(12):1085-1089.
42. Riecher-Rossler A, Rossler W, Forstl H, Meise U. Late-onset schizophrenia and late paraphrenia. Schizophr Bull 1995; 21(3):345-356.
43. Wilder-Willis KE, Shear PK, Steffen JJ, Borkin J. The relationship between cognitive dysfunction and coping abilities in schizophrenia. Schizophr Res 2002; 55(3):259-267.
44. Schultz SK, Ho BC, Andreasen NC. Clinical features characterizing young-onset and intermediate-onset schizophrenia. J Neuropsychiatry Clin Neurosci 2000; 12(4):502-505.
45. Jeste DV, Harris MJ, Pearlson GD, et al. Late-onset schizophrenia. Studying clinical validity. Psychiatr Clin North Am 1988; 11(1):1-13.
46. Wynn Owen PA, Castle DJ. Late-onset schizophrenia: epidemiology, diagnosis, management and outcomes. Drugs Aging 1999; 15(2):81-89.
47. Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997; 54(3):257-263.
48. Levy ML, Cummings JL, Fairbanks LA, et al. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996; 153(11):1438-1443.
49. Jeste DV, Wragg RE, Salmon DP, et al. Cognitive deficits of patients with Alzheimer's disease with and without delusions. Am J Psychiatry 1992; 149(2):184-189.
50. Morris S, Jeste D. Schizophrenia and other psychotic disorders. In: Ettinger W, ed. Principles of geriatric medicine and gerontology. 4th ed. New York: McGraw-Hill, 1998:1341-1349.
51. Harvey PD. Cognitive impairment in elderly patients with schizophrenia: age related changes. Int J Geriatr Psychiatry 2001; 16(suppl 1): S78-S85.
52. Arnold SE, Franz BR, Trojanowski JQ. Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesions. Neurobiol Aging 1994; 15(3):299-303.
53. Davidson M, Harvey P, Welsh KA, et al. Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. Am J Psychiatry 1996; 153(10):1274-1279.
54. Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry 2000; 61(suppl 4):27-32.
55. Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999; 7(1):70-76.
56. Mintzer J, Burns A. Anticholinergic side effects of drugs in elderly people. J R Soc Med 2000; 93(9):457-462.
57. Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002; 63(suppl 4):12-19.
58. Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psychiatry 1999; 60(suppl 8):29-41.
59. Byerly MJ, Weber MT, Brooks DL, et al. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging 2001; 18(1):45-61.
60. Masand PS. Side effects of antipsychotics in the elderly. J Clin Psychiatry 2000; 61(suppl 8):43-51.
61. Black DW, Andreasen NC. Schizophrenia, schizophreniform disorder, and delusional (paranoid) disorders. In: Hales RE, Yudofsky SC, Talbott JA, eds. Textbook of psychiatry. Washington, DC: American Psychiatric Press, 1999:425-477.
62. van de Vijver DA, Roos RA, Jansen PA, et al. Use of antipsychotics in Parkinson's disease in daily practice. Br J Clin Pharmacol 2002; 53(5):551P.
63. Sultzer DL, Gray KF, Gunay I, et al. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? J Am Geriatr Soc 2001; 49(10):1294-1300.
64. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159(3):460-465.
65. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49(12):1590-1599.
66. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54(12):2269-2276.
67. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57(4):613-620.
68. McKeith IG. Dementia with Lewy bodies. Br J Psychiatry 2002; 180:144-147.
69. Salzman C, Tune L. Neuroleptic treatment of late-life schizophrenia. Harv Rev Psychiatry 2001; 9(2):77-83.
70. Sandyk R, Awerbuch GI. Late-onset schizophrenia: relationship to awareness of abnormal involuntary movements and tobacco addiction. Int J Neurosci 1993; 71(1-4):9-19.
71. Molho ES, Factor SA. Parkinson's disease: the treatment of drug-induced hallucinations and psychosis. Curr Neurol Neurosci Rep 2001; 1(4):320-328.
72. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60(2):107-115.
73. de Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53(5):946-955.
74. Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull 2002; 28(1):43-61.
75. Barak Y. No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. J Clin Psychiatry 2002; 63(2):117-119.
76. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57(10):968-976.
77. Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002; 159(6):1058-1060.
78. Simpson MM, Goetz RR, Devlin MJ, et al. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. J Clin Psychiatry 2001; 62(9):694-700.
79. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63(5):425-433.
80. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55(6):789-794.
81. Kasper S, Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 2000; 1(4):783-801.
82. Juncos JL. Management of psychotic aspects of Parkinson's disease. J Clin Psychiatry 1999; 60(suppl 8):42-53.
83. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999; 14(3):484-487.
84. Tariot P, Schneider L, Katz I, et al. Quetiapine in nursing home residents with Alzheimer's dementia and psychosis. Paper presented at: 15th Annual Meeting of the American Association of Geriatric Psychiatry; February 24-27, 2002; Orlando, FL.
85. Green B. Focus on ziprasidone. Curr Med Res Opin 2001; 17(2):146-150.
86. Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000; 4.CD001945.
87. Goodnick PJ. Ziprasidone: profile on safety. Expert Opin Pharmacother 2001; 2(10):1655-1662.
88. Schmidt AW, Lebel LA, Howard HR, Jr., Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001; 425(3):197-201.
89. Gunasekara NS, Spencer CM, Keating GM. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2002; 62(8):1217-1251.
90. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158(11):1774-1782.
91. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 2002; 36(5):839-851.